Abstract
We analyzed survival of 102 invasive ductal, node positive breast cancer patients, treated with surgery and adjuvant chemotherapy (anthracyclines and/or taxanes) with relation to: (a) well-known clinicopathological parameters, (b) MIB-1 labeling index (LI), (c) the distribution of podoplanin-positive vessels (DPV), expression of: (d) basal markers, and (e) fascin. Lower progression risk was found for patients with tumors characterized by (i) pN1 + pN2, (ii) MIB-1LI ≤ 28%, (iii) lack of lymphatic vessels or high tumor DPV than for patients with pN3, MIB-1LI > 28%, low DPV, respectively. Cox multivariate analysis revealed that both pN3 and low DPV were negative prognostic indicators.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Anthracyclines / therapeutic use*
-
Antibiotics, Antineoplastic / therapeutic use
-
Antigens, CD34 / metabolism
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biomarkers, Tumor / metabolism*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / mortality
-
Breast Neoplasms / pathology
-
Carcinoma, Intraductal, Noninfiltrating / drug therapy*
-
Carcinoma, Intraductal, Noninfiltrating / mortality
-
Carcinoma, Intraductal, Noninfiltrating / pathology
-
Carrier Proteins / metabolism
-
Chemotherapy, Adjuvant
-
Female
-
Humans
-
Ki-67 Antigen / metabolism
-
Lymphatic Metastasis
-
Lymphatic Vessels / metabolism*
-
Lymphatic Vessels / pathology
-
Membrane Glycoproteins / metabolism*
-
Microfilament Proteins / metabolism
-
Middle Aged
-
Prognosis
-
Receptor, ErbB-2 / metabolism
-
Receptors, Estrogen / metabolism
-
Receptors, Progesterone / metabolism
-
Taxoids / therapeutic use*
-
Young Adult
Substances
-
Anthracyclines
-
Antibiotics, Antineoplastic
-
Antigens, CD34
-
Biomarkers, Tumor
-
Carrier Proteins
-
Ki-67 Antigen
-
Membrane Glycoproteins
-
Microfilament Proteins
-
PDPN protein, human
-
Receptors, Estrogen
-
Receptors, Progesterone
-
Taxoids
-
fascin
-
ERBB2 protein, human
-
Receptor, ErbB-2